Subscribe
shutterstock_1664830000_sundry_photography
Sundry Photography / Shutterstock.com
11 May 2023Big PharmaLiz Hockley

Gilead defeats US govt in billion-dollar HIV drug patent suit

Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Gilead and Teva prevail in $3.6bn antitrust trial
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Big Pharma
Gilead and Teva prevail in $3.6bn antitrust trial
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
Gilead and Teva prevail in $3.6bn antitrust trial
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress